



(86) Date de dépôt PCT/PCT Filing Date: 2007/12/06  
(87) Date publication PCT/PCT Publication Date: 2008/06/26  
(45) Date de délivrance/Issue Date: 2013/06/11  
(85) Entrée phase nationale/National Entry: 2009/06/17  
(86) N° demande PCT/PCT Application No.: IB 2007/003780  
(87) N° publication PCT/PCT Publication No.: 2008/075149  
(30) Priorité/Priority: 2006/12/18 (EP06026169.0)

(51) Cl.Int./Int.Cl. *A61K 45/06* (2006.01),  
*A61K 31/4178* (2006.01), *A61P 27/10* (2006.01)  
(72) Inventeur/Inventor:  
BENOZZI, JORGE LUIS, AR  
(73) Propriétaire/Owner:  
BENOZZI, JORGE LUIS, AR  
(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : COMPOSITIONS OPHTALMIQUES DE STIMULANTS PARASYMPATHIQUES ET D'AGENTS ANTI-INFLAMMATOIRES A UTILISER DANS LE CADRE DU TRAITEMENT DE LA PRESBYTIE  
(54) Title: OPHTHALMIC COMPOSITIONS OF PARASYMPATHETIC STIMULANTS AND ANTI-INFLAMMATORIES FOR USE IN THE TREATMENT OF PRESBYOPIA

(57) **Abrégé/Abstract:**

Ophthalmic compositions for the treatment of presbyopia, comprising combinations of parasympathomimetics and non-steroidal anti-inflammatory.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 June 2008 (26.06.2008)

PCT

(10) International Publication Number  
**WO 2008/075149 A3**

## (51) International Patent Classification:

A61K 45/06 (2006.01) A61P 27/10 (2006.01)  
A61K 31/4178 (2006.01)

## (21) International Application Number:

PCT/IB2007/003780

## (22) International Filing Date:

6 December 2007 (06.12.2007)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

06026169.0 18 December 2006 (18.12.2006) EP

## (71) Applicant and

(72) Inventor: **BENOZZI, Jorge, Luis** [IT/AR]; Santa Fr  
1769, Piso 3, CP 1060, Buenos Aires (AR).

(74) Agents: **MINOJA, Fabrizio** et al.; Via Plinio, 63, I-20129  
Milano (IT).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,  
ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,  
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,  
ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,  
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

## (88) Date of publication of the international search report:

14 August 2008

(54) Title: OPHTHALMIC COMPOSITIONS OF PARASYMPATHETIC STIMULANTS AND ANTI-INFLAMMATORIES  
FOR USE IN THE TREATMENT OF PRESBYOPIA

(57) Abstract: Ophthalmic compositions for the treatment of presbyopia, comprising combinations of parasympathomimetics and  
non-steroidal anti-inflammatory.



**WO 2008/075149 A3**

OPHTHALMIC COMPOSITIONS OF PARASYMPATHETIC  
STIMULANTS AND ANTI-INFLAMMATORIES FOR USE IN THE  
TREATMENT OF PRESBYOPIA

The present invention relates to ophthalmic compositions comprising parasympathetic stimulants and non-steroidal anti-inflammatories for use in the treatment of presbyopia.

**PRIOR ART**

5 Presbiopia, a defect in accomodation, has traditionally been treated with the use of corrective lens.

In recent years, surgery methods such as scleral expansion band, anterior ciliary sclerotomy, multifocal intraocular lenses or laser ablation of sclera retrolimbare (U.S. Pat. Nos. 6263879 and 6258082) have been  
10 suggested to correct presbyopia. All of such techniques are, however, controversial, as they do not solve the mechanical problem of accommodation (Mathews S., *Scleral Expansion Surgery does not Restore Accommodation in Human Presbyopia. Ophthalmology* 1999; 106: 873-877).

Publications concerning the treatment of presbyopia do not take into  
15 account such mechanism and aim at a surgical correction of near vision.

Lin-Kadambi suggest sympathetic and parasympathetic stimulation with adrenergic and cholinergic drugs to pharmacologically assist stabilization of the surgical results. Pharmacological treatment to treat accommodation in man has been reported in previous articles.

20 According to Rosenfield, treatment with an alpha-adrenergic antagonist induced an increase in accommodative amplitude of 1.5 D. Said action, however, only lasts two hours (Rosenfield M. The influence of Alpha-adrenergic-agents on tonic accommodation. *Current Eye Research*, vol. 9, 3, 1990, pp. 267-272).

According to Nyberg, van Alphen et al., therapy with alpha-adrenergic-agents was not satisfactory in presbyopic patients.

Nolan (U.S. Pat. No. 6,273,092) reports that topical application of acetylcholine and physostygmine to presbyopic patient gives poor results and  
5 does not solve blurred distant vision.

### **DISCLOSURE OF THE INVENTION**

The present invention relates to the pharmacological treatment of presbyopia, without surgical intervention.

It has in fact been found that alterations of visual accommodation can  
10 be treated by stimulating the sympathetic innervation which induces accommodation for near vision by use of parasympathomimetics and that said results can be maintained in time by treatment with non-steroidal anti-inflammatory (NSAIDs).

According to the invention, non-steroidal anti-inflammatories can be  
15 selected from the group consisting of diclofenac, ketorolac, bromfenac, flurbiprofen, suprofen, pranoprofen, oxyphenbutazone, bendazac, indomethacin.

Therefore, the present invention relates to ophthalmic compositions comprising combinations of parasympathomimetics and non-steroidal  
20 anti-inflammatories for the treatment of presbyopia.

The parasympathomimetics present in the combinations of the invention act on the contraction/relaxation strength of the ciliary muscle thus keeping accommodation levels stable, while NSAIDs preserve such action in time, preventing those physiological degenerations typically occurring in time with  
25 presbyopic subjects. The combinations of the invention prevent any histological and physical alterations (fibrosis and rigidity) in the ciliary muscle-zonula complex.

The present invention provides successful, stable results in emmetropic

and hypermetropic patients for at least five years; on the other hand, the invention is unsuccessful when shape modification of the lens is prevented by its rigidity.

More particularly, the present invention relates to ophthalmic compositions of pilocarpine and a NSAID for use in the treatment of presbyopia.

According to a preferred aspect of the invention, pilocarpine is in form of its hydrochloride and the NSAID is diclofenac sodium.

The compositions of the invention will contain the parasympathomimetic agent in amounts ranging from 0.5% to 4% and the NSAID in amounts ranging from 0.01 mg. to 0.1 mg.

According to a preferred aspect of the invention, the compositions will contain pilocarpine hydrochloride in concentrations ranging from 1% to 2% and diclofenac sodium in amounts ranging from 0.1% to 0.5%.

The ophthalmic compositions will be suitably formulated for the topical administration, according to well known procedure and techniques, such as those described in "Remington's Pharmaceutical Handbook", 18th edition (June 1995), Mack Publishing Co., N.Y., USA, using conventional additives well known in the pharmaceutical technique. Example of said additives are isotonic agents, such as propylene glycol, sodium chloride, potassium chloride, glycerine, sorbitol, mannitol, and the like; buffers, such as boric, phosphoric, acetic, carbonic, citric acids, and the like; stabilizers, such as ethylenediaminetetraacetic acids, sodium hydrogen sulphite, and the like; pH agents, such as citric, phosphoric, hydrochloric, acetic acids, sodium or potassium hydroxide, sodium carbonate or bicarbonate, and the like; solubilizers, such as polysorbate, polyethylene glycol, propylene glycol, macrogol 4000, and the like; thickening and dispersing agents, such as cellulose derivatives, sodium alginate, polyvinyl alcohol,

carboxyvinylpolymer, polyvinyl pyrrolidone, and the like.

The results of the pharmacological experimentation with the compositions of the invention are reported the following.

#### Materials and Methods

5 100 Presbiopic patients of both sexes, of age 40 to 65, were treated with the compositions of the invention. Exclusion criteria concerned patients with myopia or astigmatism higher than 1 dioptré, and hypermetropia greater than 3 dioptrés as well as those with corneal, lens and vitreous opacities, and chronic general pathologies.

10 4 Different groups of presbyopic population were differentiated:

Group 1: Pure presbyopics

Group 2: Presbyopics with hypermetropia

Group 3: Presbyopics with phorias

Group 4: Presbyopics with glaucoma

15 Patients of all groups were treated with eye drops of different concentrations and combinations of medicaments acting on the ocular sympathetic innervation.

Pure presbyopic patients (Group 1) were topically treated with 1% pilocarpine hydrochloride + 0.5% diclofenac sodium, at 6 hr intervals during  
20 the daily hours; treatment was suspended at night.

Presbyopics with hypermetropia (Group 2) were topically treated with 2% pilocarpine hydrochloride + 0.5% diclofenac sodium, at 6 hr intervals during the daily hours.

Presbyopic patients with phorias (Group 3) were topically treated with  
25 1% pilocarpine hydrochloride at 6 hr intervals during the daily hours, together with an orthoptic treatment directed to stimulate fusion and accommodation-convergence. This orthoptic treatment was performed by training the patient in the use of an exercising software, which then the patient used without the need

of professional help. 3-Minute sessions were carried out daily for a period of 15 days and were repeated yearly.

Presbyopics patients with glaucoma (Group 4), were topically treated with 2% pilocarpine hydrochloride + 0.5% diclofenac sodium at 6 hr intervals during the 24 hours i.e. including nighttime. Regular hypotensive medication used by the patients was maintained.

All patients were monitored after one week treatment and monthly during the first three months to evaluate dosage and side-effects.

Controls included:

10 Near and distant visual sharpness

Myosis

Conjunctiva

Ocular tension

Astenopia

15 Tolerance

- When visual sharpness was not desired, dosages were changed and accommodation was checked.
- When myosis was not tolerated, argon laser iridoplasty was carried out by shooting in 360° spots in the iris constrictor muscle. The laser intensity and the size of the spot, were adapted to the intensity of iris pigmentation.
- Topical treatment was modified in case of conjunctiva inflammation.
- When ocular tension was not ideal, hypotensive medication was modified prior to presbyopia treatment.
- Orthoptic treatment was corrected in case of patient astenopia.
- Treatment was suspended in case of intolerance to medication.

## RESULTS AND CONCLUSIONS

100 Patients were treated: 2 patients showed intolerance to pilocarpine

hydrochloride (diarrhoea and dyspepsia), 2 patients (presbyopics with hypermetropia) did not obtain the desired improvement in visual sharpness.

10 patients have been under treatment for 6 years

20 patients have been under treatment for 5 years

5 30 patients have been under treatment for 4 years

40 patients have been under treatment for 3 years

80 patients have been under treatment for 2 years

96 patients have been under treatment for 1 year.

#### Results

10 **Group 1:** 100% of patients experienced correction of presbyopia.

**Group 2:** 48% of patients abandoned the use of eyeglasses, 44% only use eyeglasses for near vision with 2 to 3 dioptres less than those required before treatment, according to their original hypermetropia, and 8% of patients abandoned treatment.

15 **Group 3:** 89.47% of patients abandoned eyeglasses and have good near vision, 10.53% did not experience improvements in their near vision.

**Group 4:** 100% of patients had good near vision without glasses and maintained their ocular hypertension under control.

20 Patients who discontinued the treatment experienced regression of visual sharpness to that before treatment. No worsening of presbyopia was observed, conversely in some patients accommodation was better than before starting treatment.

**CLAIMS**

1. An ophthalmic composition for the treatment of presbyopia, comprising a combination of at least one parasympathomimetic agent and at least one non-steroidal anti-inflammatory agent.
2. The composition as claimed in claim 1, wherein the parasympathomimetic agent is pilocarpine or a salt thereof.
3. The composition as claimed in claim 1, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac, ketorolac, bromfenac, flurbiprofen, suprofen, pranoprofen, oxyphenbutazone, bendazac, and indomethacin.
4. The composition as claimed in claim 3, wherein the non-steroidal anti-inflammatory agent is diclofenac or a salt thereof.
5. The composition as claimed in any one of claims 1 to 3, containing pilocarpine hydrochloride in a concentration ranging from 1% to 2% and diclofenac sodium in an amount ranging from 0.1% to 0.5%.
6. Use of at least one parasympathomimetic agent and at least one non-steroidal anti-inflammatory agent for the preparation of a medicament for the treatment of presbyopia.
7. The use as claimed in claim 6, wherein the parasympathomimetic agent is pilocarpine or a salt thereof.
8. The use as claimed in claim 6, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac, ketorolac, bromfenac, flurbiprofen, suprofen, pranoprofen, oxyphenbutazone, bendazac, and indomethacin.
9. The use as claimed in claim 8, wherein the non-steroidal anti-inflammatory agent is diclofenac or a salt thereof.